(Total Views: 543)
Posted On: 11/16/2019 7:34:26 AM
Post# of 154055
Nice, I just posted this on the two ihub big boards, many we get a few interested there as well.
$CYDY-10M volume last week, largest ever, vol before price
You will not find an otc biotech this close to drug approval with this many indications at 30c.
Why?
$90M licensing deal close for just HIV in US to being announced
Final BLA submission for combo HIV next month
Cancer data for first patient with metastatic triple negative breast cancer came back excellent.
Cancer trial for all metastatic cancer to be submitted (IND)
NASH large animal study exceptional data released this month
Leronlimab has had no serious adverse events in over 800 patients in over 10 years... unheard of in HIV or cancer
Leronlimab has no documented patient HIV mutation, unheard of in HIV, some patients have been on it 5 years. They use 3 drugs normally for HIV patients, but because of this, they may get approval with HIV with just the one drug—-leronlimab.
$CYDY-10M volume last week, largest ever, vol before price
You will not find an otc biotech this close to drug approval with this many indications at 30c.
Why?
$90M licensing deal close for just HIV in US to being announced
Final BLA submission for combo HIV next month
Cancer data for first patient with metastatic triple negative breast cancer came back excellent.
Cancer trial for all metastatic cancer to be submitted (IND)
NASH large animal study exceptional data released this month
Leronlimab has had no serious adverse events in over 800 patients in over 10 years... unheard of in HIV or cancer
Leronlimab has no documented patient HIV mutation, unheard of in HIV, some patients have been on it 5 years. They use 3 drugs normally for HIV patients, but because of this, they may get approval with HIV with just the one drug—-leronlimab.
(2)
(0)
